Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686722 | 1.00 | GAA (0.58) | GAAMAPTL3MBTL1KDM4ETDP1 | |
| SCHEMBL18285011 | 0.88 | GAA (0.50) | GAAMAPTL3MBTL1KDM4ETDP1 | |
| SCHEMBL10791981 | 0.84 | ELANE (0.53) | GAAKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL12849869 | 0.84 | RAB9A (0.54) | GAAKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL10143994 | 0.84 | RAB9A (0.54) | GAAKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL4181084 | 0.84 | SMN1; SMN2 (0.56) | GAAMAPTTDP1SMN1; SMN2KMT2A | |
| SCHEMBL21732631 | 0.83 | RAB9A (0.50) | GAAMAPTL3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL4409741 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2ARAB9AALDH1A1HPGD | |
| SCHEMBL15234281 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2ARAB9AALDH1A1HPGD | |
| SCHEMBL3659103 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2ARAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-117126073-A | Arylation derivative containing benzamide structure compound and preparation method thereof | 浙江工业大学 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| CN-106831665-B | Enantioselective synthesis γ-substitution-gamma-butyrolacton and δ-substitution-δ-valerolactone method | 大连大学 | 2019-06-18 | — | — | CN | disclosed |
| CN-109563054-A | Novel arylethene derivative and pharmaceutical composition containing the same as active ingredient | 克米迈迪有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109415313-A | New aryl ethene derivatives and using the new aryl ethylene as the pharmaceutical composition of effective component | 克米迈迪有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-106831665-A | Enantioselective synthesis γ replaces the method that gamma butyrolactone and δ replace δ valerolactones | 大连大学 | 2017-06-13 | — | — | CN | disclosed |
| CN-103724330-B | The effective combined utilization of monobactams antibiotic and beta-lactamase inhibitor | BASLIER PHARMACEUTICAL AG (CH) | 2015-08-19 | — | — | CN | disclosed |
| CN-102988362-B | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG | 2014-11-05 | — | — | CN | disclosed |
| CN-103724330-A | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG | 2014-04-16 | — | — | CN | disclosed |
| CN-102988362-A | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG | 2013-03-27 | — | — | CN | disclosed |
| EP-0748247-B1 | Macrocyclic antibiotics as separation agents | UNIV MISSOURI (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-0017485-B1 | A PROCESS FOR ENZYMATIC PRODUCTION OF PEPTIDES | DE FORENEDE BRYGGERIER A/S (DK) | 1984-09-26 | — | — | EP | disclosed |
| WO-1980002157-A1 | A PROCESS FOR ENZYMATIC PRODUCTION OF PEPTIDES | FORENEDE BRYGGERIER AS (DK) | 1980-10-16 | — | — | WO | disclosed |
| EP-0017485-A1 | A process for enzymatic production of peptides | DE FORENEDE BRYGGERIER A/S (DK) | 1980-10-15 | — | — | EP | disclosed |
| US-4146432-A | ADSORPTION ON ION EXCHANGE RESINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | GAA 8/4885MAPT 326/4885L3MBTL1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.